Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 56.19 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 72.70 | Oscillator | Neutral |
| Williams %R (14) | -14.73 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.20 (Hist 0.13) | Oscillator | Strong Buy |
| Average Directional Index (14) | 22.63 (+DI 18.2 / -DI 26.5) | Trend | Sell |
| EMA 20 | 53.50 | MA | Buy |
| SMA 20 | 53.01 | MA | Buy |
| EMA 50 | 53.56 | MA | Buy |
| SMA 50 | 53.48 | MA | Buy |
| SMA 200 | 56.91 | MA | Strong Sell |
Current price $54.53
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 12, 26 | UBS | maintain | Buy | Buy |
| Sep 18, 26 | Stephens & Co. | maintain | Overweight | Overweight |
| Sep 17, 26 | Roth Capital | maintain | Buy | Buy |
| Sep 14, 26 | UBS | maintain | Buy | Buy |
| Sep 14, 26 | RBC Capital | maintain | Outperform | Outperform |
| Aug 17, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 12, 26 | UBS | maintain | Buy | Buy |
| Aug 11, 26 | Barclays | maintain | Overweight | Overweight |
| Jul 17, 26 | Stephens & Co. | maintain | Overweight | Overweight |
TTM vs. 5-year historical average (annual ratios)
| Metric | CRC | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -41.0x | 8.1x · sector 14.8x | Discount |
| Forward P/E (FY26E) | 13.1x | EPS est. 4.18 | Discount |
| Price / Book | 1.4x | 1.6x | In line |
| Price / Sales | 1.2x | 1.2x | In line |
| EV / EBITDA | 11.9x | 4.6x | Elevated |
| Return on equity | -3.6% | — | Weak |
| Gross margin | 46.4% | 45.9% | In line |
| Debt / Equity | 0.40 | 0.34 | Conservative |
| Piotroski / Altman Z | 5/9 | Z 1.58 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 12, 26 | Bys Jay A. | officer: EVP & Chief Commercial Officer | S-Sale | 11,907 @ $54.00 | $643.0K |
| Sep 4, 26 | Bys Jay A. | officer: EVP & Chief Commercial Officer | S-Sale | 11,907 @ $54.00 | $643.0K |
| Aug 10, 26 | Bys Jay A. | officer: EVP & Chief Commercial Officer | S-Sale | 11,907 @ $54.00 | $643.0K |
| Jul 13, 26 | Bys Jay A. | officer: EVP & Chief Commercial Officer | S-Sale | 11,907 @ $54.00 | $643.0K |
| Jun 19, 26 | Hayat Omar | officer: EVP & Chief Operating Officer | A-Award | 7,312 | — |
| Jun 19, 26 | Hayat Omar | officer: EVP & Chief Operating Officer | F-InKind | 3,945 @ $55.30 | $218.2K |
| Jun 19, 26 | Hayat Omar | officer: EVP & Chief Operating Officer | F-InKind | 2,139 @ $55.30 | $118.3K |
| Jun 4, 26 | Bys Jay A. | officer: EVP & Chief Commercial Officer | S-Sale | 11,907 @ $61.68 | $734.4K |
FY2025 · 10-K disclosure
Stock news · updated daily
[url="]Genmab A/S[/url] (Nasdaq: GMAB) and [url="]Incyte[/url] (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's
Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte's investigational, potent and se
Ziihera (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 202
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free surv
– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw – – In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and a 99.8% negative predictive value for lung cancer in its intended use population – BRISBANE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based tests, today announced the launch of SimpleScreen™ Lung and a first-of-its-kind offering that enables eligible patients to be screened for both lung and colorectal cancer (CRC) through a single blood draw, using two independently validated, indication-specific tests.
/C O R R E C T I O N - AbbVie/PR NewswireNORTH CHICAGO, Ill., Oct. 18, 2026In the news release, AbbVie to Present Data at the 2026 European Society for Medical
[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology wi
Incyte (Nasdaq:INCY) today announced that it will present new data from its oncology portfolio during the European Society of Medical Oncology (ESMO) Congress 2
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 10, 2026 | 1.36 | 0.99 | Miss -27.2% | $1.30B |
| May 5, 2026 | 0.83 | 0.88 | Beat 6.0% | $119.0M |
| Mar 2, 2026 | 0.49 | 0.47 | Miss -4.1% | $924.0M |
| Nov 4, 2025 | 1.31 | 1.46 | Beat 11.5% | $878.0M |
| Aug 5, 2025 | 0.91 | 1.10 | Beat 20.9% | $816.0M |
| May 6, 2025 | 0.83 | 1.07 | Beat 28.9% | $900.0M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 14, 2026 | 2026-10-14 20:05:33 | View |
| 8-K | Oct 13, 2026 | 2026-10-13 08:31:23 | View |
| SD | Sep 17, 2026 | 2026-09-17 16:48:45 | View |
| 4 | Sep 8, 2026 | 2026-09-08 20:22:48 | View |
| 4 | Aug 12, 2026 | 2026-08-12 18:13:16 | View |
| 10-Q | Aug 10, 2026 | 2026-08-10 15:08:13 | View |
| 8-K | Aug 10, 2026 | 2026-08-10 08:06:09 | View |
| SC 13G/A | Jul 27, 2026 | 2026-07-27 16:25:25 | View |
| 4 | Jul 14, 2026 | 2026-07-14 18:04:34 | View |
| 8-K | Jul 14, 2026 | 2026-07-14 09:00:34 | View |
Proxy statement (DEF 14A) disclosures